Depression risk higher among long-term breast cancer survivors than women without breast cancer historyDepression risk higher among long-term breast cancer survivors than women without breast cancer history
Long-term breast cancer survivors have a higher risk for developing depression, particularly if they have insomnia, according to a study published online Oct. 10 in SLEEPJ.
Father–son team integrates AI into cancer researchFather–son team integrates AI into cancer research
For more than three decades, USF Distinguished University Professor Dmitry Goldgof in the Bellini College of Artificial Intelligence, Cybersecurity and Computing has been at the forefront of artificial intelligence research. His son, Dr. Gregory Goldgof, is a physician scientist at Memorial Sloan Kettering Cancer Center in New York City, where he serves as the director of Artificial Intelligence for Hematopathology. Trained in both computer science and medicine, Goldgof leads a translational AI laboratory developing deep learning tools to analyze diseases of the blood and bone marrow.
Antibody-Drug Conjugate Shows Benefits in HER2-Positive Early Breast CancerAntibody-Drug Conjugate Shows Benefits in HER2-Positive Early Breast Cancer
(MedPage Today) — The addition of neoadjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved pathologic complete response (pCR) rates compared with anthracycline-containing chemotherapy in high-risk, HER2-positive early breast…
New study elucidates obesity’s role in fueling breast cancer progressionNew study elucidates obesity’s role in fueling breast cancer progression
Obesity and cancer are two major health challenges of our time, yet the link between them remains only partially understood. New research now highlights a molecular chain of events in estrogen receptor-positive breast cancer, revealing how leptin, a hormone produced by fat cells, signals cancer cells to grow. This leads to increased activity of the enzyme stearoyl-CoA desaturase (SCD), which fuels the growth and motility of cancer cells.
Tracking RNA levels reveals new clues in triple-negative breast cancer progressionTracking RNA levels reveals new clues in triple-negative breast cancer progression
When researchers look for potential cancer therapy targets, they typically go after protein-coding genes that participate in disease progression. Disrupt them and negate whatever role they play in cancer’s development or spread. Researchers at Cold Spring Harbor Laboratory (CSHL) have also been working on another kind of target. They’re studying a long non-coding RNA called MALAT1. So far, it’s been linked to more than 20 different types of tumors.
Connecticut doctors are part of new cancer trials: The goal? ‘Eradicate all deaths from breast cancer’Connecticut doctors are part of new cancer trials: The goal? ‘Eradicate all deaths from breast cancer’
About 170,000 women in the United States are living with metastatic breast cancer—or cancer that has spread to other organs—and eventually leads to death.
Hims & Hers Weight Loss Shots: What You Need To Know About The GLP-1s And Compounded DrugsHims & Hers Weight Loss Shots: What You Need To Know About The GLP-1s And Compounded Drugs
Post Content Post Content
First it was Ozempic. Now the peptide gold rush is here — and it’s dangerousFirst it was Ozempic. Now the peptide gold rush is here — and it’s dangerous
Ozempic changed everything: Millions of Americans who have discovered the transformative power of one peptide are chasing their next fix Ozempic changed everything: Millions of Americans who have discovered the transformative power of one peptide are chasing their next fix
STAT+: Is the White House’s deal with pharma on GLP-1 drugs a game changer? STAT+: Is the White House’s deal with pharma on GLP-1 drugs a game changer?
President Trump last week hailed his deal with pharma companies to cut the price of blockbuster weight loss drugs as a major win for his administration and for increasing drug affordability. The question is how big of a difference the agreement will make for patients. The deal is expected to significantly expand access to GLP-1 Read More
Gordon Ramsay calls Ozempic restaurant menus ‘absolute bulls—‘ in profanity-filled rantGordon Ramsay calls Ozempic restaurant menus ‘absolute bulls—‘ in profanity-filled rant
Gordon Ramsay didn’t hold back when speaking out on whether he would alter his restaurants’ menus to cater to diners who are taking popular weight loss drugs including Ozempic and Mounjaro. During a recent interview with The Sunday Times, the 59-year-old celebrity chef was asked whether he would create special, smaller-portion menus for patrons using Read More